Corleen M. Roche bought $38k of CGON
CFO & Secretary at CG Oncology, Inc.. 2,000 shares at an average of $19.00, traded Jan 29, 2024, filed Jan 31, 2024.
Score components
- +22RoleCFO
- +6Trade size$38k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +10Price context6% above the 52-week low
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +18.0%, 3m +9.0%, 6m -10.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-009432, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 29, 2024 | POpen-market purchase Common Stock | +2,000 | $19.00 | $38k | 2,000 | Jan 31, 2024 |
Related signals
Other insiders at CG Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | CG Oncology, Inc. | Leonard E Post director | $73k 1,000 shares | -100% | |
| 8Weak | CG Oncology, Inc. | Leonard E Post director | $75k 1,000 shares | -100% | |
| 16Weak | CG Oncology, Inc. | Leonard E Post director | $71k 1,000 shares | -100% | |
| 33Weak | CG Oncology, Inc. | James Mulay director | $1.8M 24,165 shares | -100% | |
| 31Weak | CG Oncology, Inc. | Brian Guan-Chyun Liu director | $25M 371,085 shares | +24% | |
| 23Weak | CG Oncology, Inc. | Leonard E Post director | $350k 5,000 shares | -100% | |
| 22Weak | CG Oncology, Inc. | Leonard E Post director | $325k 5,000 shares | -100% | |
| 18Weak | CG Oncology, Inc. | James Mulay director | $118k 1,964 shares | -300% | |
| 15Weak | CG Oncology, Inc. | Leonard E Post director | $55k 1,000 shares | -100% | |
| 25Weak | CG Oncology, Inc. | James Mulay director | $1.1M 15,600 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.